TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30408271

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) therapy
Number of subjects: 38
Study: 30201039

Group type: EXPERIMENTAL
Intervention: E-WORTH intervention combined with streamlined HIV testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Streamlined HIV testing alone
Number of subjects: 0
Study: 27269946

Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 521

Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Fulvestrant plus palbociclib
Number of subjects: 521

Group type: COMPARATOR
Intervention: Fulvestrant plus placebo
Number of subjects: 521
Study: 24899464

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Why WAIT (intensive diabetes medical and weight management program)
Number of subjects: 38
Study: 22329987

Group type: EXPERIMENTAL
Intervention: Short-term energy surfeit treatment (BOOST®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short-term post-absorptive state (water only)
Number of subjects: 0
Study: 21094429

Group type: EXPERIMENTAL
Intervention: Resource communication
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Planning
Number of subjects: 534

Group type: COMPARATOR
Intervention: Control
Number of subjects: 534
Study: 22126936

Group type: EXPERIMENTAL
Intervention: Cystatin C
Number of subjects: 16401

Group type: EXPERIMENTAL
Intervention: CKD-EPI
Number of subjects: 16401
Study: 15939317

Group type: EXPERIMENTAL
Intervention: Budesonide 400 mcg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Budesonide 800 mcg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 51
Study: 12459618

Group type: EXPERIMENTAL
Intervention: Experimental mouthrinse containing propolis SNB‐RS
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 6
Study: 10483896

Group type: EXPERIMENTAL
Intervention: Glutamine-enriched enteral nutrition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard enteral nutrition)
Number of subjects: 0
Study: 8733890

Group type: EXPERIMENTAL
Intervention: Erucic acid (component of Lorenzo's oil)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 39
Study: 1660825

Group type: EXPERIMENTAL
Intervention: Oral administration of conjugated oestrogen, dosage not specified, duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atropine sulphate, dosage not specified, duration not specified.
Number of subjects: 0
Study: 7041323

Group type: EXPERIMENTAL
Intervention: Multipuncture BCG (50 to 250 X 10(6) viable units)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Intradermal BCG (0.4 to 0.9 X 10(6) viable units)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no BCG immunotherapy)
Number of subjects: 92
Study: 29730966

Group type: EXPERIMENTAL
Intervention: Collaborative learning activity using virtual patients (VPs)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Independent learning activity using virtual patients (VPs)
Number of subjects: 158
Study: 27633286

Group type: EXPERIMENTAL
Intervention: Real rTMS stimulation (10 sessions, 20 trains of 5 seconds at 10 Hz)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sham stimulation (control group)
Number of subjects: 47
Study: 25557828

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: CYP2C19*2 loss‐of‐function (LOF) carriers
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Non-carriers
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Gain of function carriers
Number of subjects: 302
Study: 23645178

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Essential-oils mouthwash
Number of subjects: 50
Study: 20543727

Group type: EXPERIMENTAL
Intervention: 1.37-kg overweight implement (OVRWGHT1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2.27-kg overweight implement (OVRWGHT2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Regulation weight (STAND)
Number of subjects: 10
Study: 18271706

Group type: EXPERIMENTAL
Intervention: Paliperidone-ER
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15855885

Group type: EXPERIMENTAL
Intervention: Domestic ELF-EMF exposure above the upper tertile at low current configuration
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Daily alcohol intake
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) above the median
Number of subjects: 51
Study: 12952836

Group type: EXPERIMENTAL
Intervention: MMP-3
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: MMP-9
Number of subjects: 25

Group type: COMPARATOR
Intervention: MMP-2
Number of subjects: 25
Study: 10928520

Group type: EXPERIMENTAL
Intervention: Reteplase for arterial occlusions
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Reteplase for venous occlusions
Number of subjects: 37
Study: 8905028

Group type: EXPERIMENTAL
Intervention: Three-weekly chemotherapy (cyclophosphamide 600 mg/m2, carboplatin 300 mg/m2, doxorubicin 50 mg/m2, ifosfamide 5 g/m2)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Four-weekly chemotherapy (cyclophosphamide 600 mg/m2, carboplatin 300 mg/m2, doxorubicin 50 mg/m2, ifosfamide 5 g/m2)
Number of subjects: 144
Study: 1756257

Group type: EXPERIMENTAL
Intervention: Ki-67 positivity (group III)
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Ki-67 reactivity
Number of subjects: 568

Group type: COMPARATOR
Intervention: Ki-67 groups I and II
Number of subjects: 568

Group type: COMPARATOR
Intervention: Ki-67 groups II and III
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: pT2 and G-II carcinomas
Number of subjects: 568
Study: 6802691

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCZ) 50 mg once daily (or 50 mg twice a day for 2 patients)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCZ) plus Nadolol (40 mg to 240 mg once daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nadolol (40 mg to 240 mg once daily)
Number of subjects: 32
Study: 29562396

Group type: EXPERIMENTAL
Intervention: Radiofrequency treatment with ultrasound guidance
Number of subjects: 128
Study: 26935509

Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW) technique
Number of subjects: 24

Group type: COMPARATOR
Intervention: Walking without NW poles
Number of subjects: 24
Study: 24221577

Group type: EXPERIMENTAL
Intervention: Irradiated organic manuka honey (5 ml, four times a day during radiation treatment plus seven days)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo gel (5 ml, four times a day during radiation treatment plus seven days)
Number of subjects: 81
Study: 22819187

Group type: EXPERIMENTAL
Intervention: Initiation of recombinant FSH/GnRH antagonist/recombinant LH/hCG on day 1 (n = 39)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Initiation of recombinant FSH/GnRH antagonist/recombinant LH/hCG on day 4 (n = 41)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Day 1 group
Number of subjects: 80
Study: 20546568

Group type: EXPERIMENTAL
Intervention: Worksite prevention program consisting of two individual training sessions by a physical therapist, a Rest-Break tool, and two empowerment training sessions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 18669713

Group type: EXPERIMENTAL
Intervention: Ritgen's maneuver
Number of subjects: 1423

Group type: COMPARATOR
Intervention: Simple perineal support
Number of subjects: 1423
Study: 16355621

Group type: EXPERIMENTAL
Intervention: Huoxue Jieyu decoction (HJD)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Chlorimipramine (anafranil)
Number of subjects: 90
Study: 11985944

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.35 g/kg of fat-free mass)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 20
Study: 10215716

Group type: EXPERIMENTAL
Intervention: Digital palpation technique after training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reusable laryngeal mask airway
Number of subjects: 20

Group type: COMPARATOR
Intervention: Disposable laryngeal mask airway
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low initial pressure
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High initial pressure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pre-training phase
Number of subjects: 20
Study: 8536758

Group type: EXPERIMENTAL
Intervention: Paclitaxel and cisplatin (135 mg/m2 or 175 mg/m2 of paclitaxel and 50 mg/m2, 75 mg/m2, or 100 mg/m2 of cisplatin)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Paclitaxel and cisplatin
Number of subjects: 15
Study: 2195035

Group type: EXPERIMENTAL
Intervention: Double latex gloves (Group I)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cloth outer gloves with latex inner gloves (Group II)
Number of subjects: 50
Study: 343907

Group type: EXPERIMENTAL
Intervention: DTIC + cyclophosphamide
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: DTIC + vinblastine
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: DTIC + procarbazine
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 101
Study: 31944826

Group type: EXPERIMENTAL
Intervention: RADAR system ablation
Number of subjects: 64
Study: 31640994

Group type: EXPERIMENTAL
Intervention: TiM plus usual care
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 40
Study: 28228504

Group type: EXPERIMENTAL
Intervention: Fat emulsion structure (4 different emulsions)
Number of subjects: 17
Study: 25592751

Group type: EXPERIMENTAL
Intervention: 14.5 g spices (black pepper, cinnamon, cloves, garlic, ginger, oregano, paprika, rosemary, and turmeric)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (low spice meal)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Spice blend and individual spices (in vitro)
Number of subjects: 20
Study: 24151277

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) administration (35 mg once weekly for six months)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Delayed ALN administration (not specified dosage, started four months after surgery)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Both groups (ALN and no-ALN)
Number of subjects: 80
Study: 22076970

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBGT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Group psychotherapy (GPT)
Number of subjects: 45
Study: 19363053

Group type: EXPERIMENTAL
Intervention: OptiSense 1699T lead
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional pacing lead
Number of subjects: 63
Study: 17942873

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Both prednisolone and acyclovir
Number of subjects: 551

Group type: COMPARATOR
Intervention: No prednisolone
Number of subjects: 551

Group type: COMPARATOR
Intervention: No acyclovir
Number of subjects: 551
Study: 15284267

Group type: EXPERIMENTAL
Intervention: Health-related quality of life measures (HRQL) including Short Form-36 (SF-36) for ages > 13 years and Child Health Questionnaire-Child Form 87 (CHQ-CF87) for ages <= 13 years
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Maximal cardiac index (MCI)
Number of subjects: 127
Study: 11527909

Group type: EXPERIMENTAL
Intervention: 0.5% ferric hyaluronate gel
Number of subjects: 77

Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 77
Study: 9428861

Group type: EXPERIMENTAL
Intervention: D-myo-inositol-1,2,6-trisphosphate (1,2,6-IP3) intravenous bolus dose of 240 mg followed by continuous infusion at 90 mg/h for 24 h
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: D-myo-inositol-1,2,6-trisphosphate (1,2,6-IP3)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 24
Study: 7641722

Group type: EXPERIMENTAL
Intervention: alfentanil 30 micrograms kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ketamine 1.5 mg kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (control)
Number of subjects: 30
Study: 2621178

Group type: EXPERIMENTAL
Intervention: Acyclovir, 800 mg tid
Number of subjects: 5
Study: 1251139

Group type: EXPERIMENTAL
Intervention: Prophylaxis replacement therapy with biweekly administration of 7.5 U/kg of factor IX concentrate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Prophylaxis replacement therapy with weekly administration of 15 U/kg of factor IX concentrate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Prophylaxis replacement therapy (both schemes)
Number of subjects: 10
Study: 31448433

Group type: EXPERIMENTAL
Intervention: Upadacitinib (1 mg to 48 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tofacitinib (5 mg BID)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upadacitinib (∼12 mg BID)
Number of subjects: 0
Study: 31221115

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation (Pre-CRT) - two cycles of S-1 and oxaliplatin (SOX), followed by chemoradiation, then surgery and three more cycles of SOX chemotherapy.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative chemotherapy (Pre-CT) - three cycles of SOX, followed by surgery and three more cycles of SOX chemotherapy.
Number of subjects: 0
Study: 28646390

Group type: EXPERIMENTAL
Intervention: Laser + topical drug (calcipotriol ointment)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Drug alone (calcipotriol ointment)
Number of subjects: 5
Study: 26057652

Group type: EXPERIMENTAL
Intervention: Cincinnati Prehospital Stroke Scale (CPSS)
Number of subjects: 246

Group type: COMPARATOR
Intervention: National Guidelines for Telephone Triage Tool (NGTT)
Number of subjects: 246
Study: 22976882

Group type: EXPERIMENTAL
Intervention: Direct memory test (recognition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indirect memory test (identification)
Number of subjects: 0
Study: 21640878

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Oral B mouthwash
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Persica mouthwash
Number of subjects: 160

Group type: COMPARATOR
Intervention: Distilled deionized water
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: All mouthwashes (Chlorhexidine, Oral B, Persica)
Number of subjects: 160
Study: 19373095

Group type: EXPERIMENTAL
Intervention: EasyTube (EZT)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Laryngeal tube S II (LTS II)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Endotracheal tube
Number of subjects: 88
Study: 16769002

Group type: EXPERIMENTAL
Intervention: Classical surgery (ligature and section at the sapheno-femoral junction and collateral veins, with saphenectomy)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 3-S saphenectomy technique (sclerosis injection at the sapheno-femoral junction with microfoam through a catheter, with saphenectomy and distal phlebectomies)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Classical surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: 3-S saphenectomy technique
Number of subjects: 100
Study: 12685950

Group type: EXPERIMENTAL
Intervention: Hypertomic saline enema
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hyoscinbutylbromide in infusion
Number of subjects: 45

Group type: COMPARATOR
Intervention: I/V fluids only
Number of subjects: 45
Study: 10606475

Group type: EXPERIMENTAL
Intervention: HBO‐4 (hyperbaric oxygen at 4 atmospheres)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Air (control group)
Number of subjects: 48
Study: 8596107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 1753422

Group type: EXPERIMENTAL
Intervention: 200 mg of norfloxacin (chemoprophylaxis)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional therapy (without any antimicrobials except when overt UTI occurred)
Number of subjects: 20
Study: 6760378

Group type: EXPERIMENTAL
Intervention: 100 mg of azathioprine
Number of subjects: 154

Group type: COMPARATOR
Intervention: 10-15 mg of prednisone daily
Number of subjects: 154
Study: 3882107

Group type: EXPERIMENTAL
Intervention: Intravenous BRL 26921
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30442864

Group type: EXPERIMENTAL
Intervention: Home-based kidney care program
Number of subjects: 98

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 98
Study: 26795566

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 25083759

Group type: EXPERIMENTAL
Intervention: tDCS over DLPFC
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: tDCS over primary motor cortex
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 21
Study: 22860481

Group type: EXPERIMENTAL
Intervention: Expert role modeling video
Number of subjects: 275

Group type: COMPARATOR
Intervention: Control group (no expert role modeling video)
Number of subjects: 275
Study: 20237060

Group type: EXPERIMENTAL
Intervention: Protein-enriched diet
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 13
Study: 18341601

Group type: EXPERIMENTAL
Intervention: EMD/SBC (Enamel Matrix Derivative/Synthetic Bone Graft)
Number of subjects: 73

Group type: COMPARATOR
Intervention: EMD (Enamel Matrix Derivative)
Number of subjects: 73
Study: 15712339

Group type: EXPERIMENTAL
Intervention: Uncertainty management intervention delivered during four weekly telephone sessions with cognitive-behavioral strategies and a self-help manual.
Number of subjects: 509

Group type: COMPARATOR
Intervention: Usual care control condition.
Number of subjects: 509
Study: 14717307

Group type: EXPERIMENTAL
Intervention: Elective Caesarean delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaginal birth
Number of subjects: 0
Study: 10552322

Group type: EXPERIMENTAL
Intervention: Increased intra-abdominal pressure (IAP) at 40%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Increased intra-abdominal pressure (IAP) at 80%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Wearing an abdominal belt
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no belt)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no IAP)
Number of subjects: 10
Study: 8563411

Group type: EXPERIMENTAL
Intervention: Full-text search of NEJM
Number of subjects: 0

Group type: COMPARATOR
Intervention: MEDLINE search
Number of subjects: 0
Study: 1685665

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 50 mg remoxipride
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 100 mg remoxipride
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Immediate release capsules (A and B) of 100 mg remoxipride
Number of subjects: 15
Study: 6124989

Group type: EXPERIMENTAL
Intervention: Co-dergocrine (hydergine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31680269

Group type: EXPERIMENTAL
Intervention: Routine blood glucose assessment at intervention hospitals; automatic requests for glycated haemoglobin (HbA1c) assessment and notification of diabetes services about patients with blood glucose levels of 14 mmol/L or more.
Number of subjects: 133837

Group type: COMPARATOR
Intervention: Routine blood glucose assessment at control hospitals.
Number of subjects: 133837
Study: 27998657

Group type: EXPERIMENTAL
Intervention: HXLPE
Number of subjects: 54

Group type: COMPARATOR
Intervention: UHMWPE
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study: 27585441

Group type: EXPERIMENTAL
Intervention: Low WOMAC Pain group (0-25)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Medium WOMAC Pain group (26-40)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: High WOMAC Pain group (41-100)
Number of subjects: 202
Study: 24082155

Group type: EXPERIMENTAL
Intervention: High-intensity intermittent endurance training (30 s at 100% of max workload, 30 s at rest, for 45 min/day for 12 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-intensity intermittent endurance training
Number of subjects: 100

Group type: COMPARATOR
Intervention: No exercise advice
Number of subjects: 100
Study: 21988478

Group type: EXPERIMENTAL
Intervention: Coping self-efficacy in negative situations
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Coping self-efficacy in positive situations
Number of subjects: 292
Study: 19916254

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided supraclavicular brachial plexus block with 20 mL of 0.75% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nerve stimulation supraclavicular brachus plexus block with 20 mL of 0.75% ropivacaine
Number of subjects: 60
Study: 17454528

Group type: EXPERIMENTAL
Intervention: 20-s rest intervals
Number of subjects: 18

Group type: COMPARATOR
Intervention: 80-s rest intervals
Number of subjects: 18
Study: 15140461

Group type: EXPERIMENTAL
Intervention: Enhanced print version (simpler language, topic headings, pictures)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Original written forms
Number of subjects: 233

Group type: COMPARATOR
Intervention: Narrated videotapes
Number of subjects: 233

Group type: COMPARATOR
Intervention: Self-paced PowerPoint presentations via laptop computer (bulleted print information, pictures, narration)
Number of subjects: 233

Group type: COMPARATOR
Intervention: All formats
Number of subjects: 233
Study: 12862299

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (5 mg/kg as a 30 min infusion, followed by 10 mg/kg during 20 hours in GIKM solution)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (1000 ml of GIKM alone)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 160
Study: 9831683

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 0
Study: 8523058

Group type: EXPERIMENTAL
Intervention: Fluorouracil plus levamisole (450 mg/m2 IV daily for 5 days, then weekly for 48 weeks; levamisole 50 mg orally three times daily for 3 days every 2 weeks for 1 year)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Fluorouracil plus levamisole
Number of subjects: 318